181 related articles for article (PubMed ID: 38194043)
1. Preclinical evaluation of the theranostic potential of
Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
[TBL] [Abstract][Full Text] [Related]
2. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.
Chen W; Li M; Younis MH; Barnhart TE; Jiang D; Sun T; Lang JM; Engle JW; Zhou M; Cai W
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):861-870. PubMed ID: 34519889
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
4. Theranostic role of
Yang Q; Chen Z; Qiu Y; Huang W; Wang T; Song L; Sun X; Li C; Xu X; Kang L
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1246-1260. PubMed ID: 38135849
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
6. Theranostic application of
Li C; Liu J; Yang X; Yang Q; Huang W; Zhang M; Zhou D; Wang R; Gong J; Miao Q; Kang L; Yang J
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):168-183. PubMed ID: 36063202
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
8. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
9. Development of [
Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
[TBL] [Abstract][Full Text] [Related]
10. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
11. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
12.
Giesen D; Hooge MNL; Nijland M; Heyerdahl H; Dahle J; de Vries EGE; Pool M
Sci Rep; 2022 Apr; 12(1):6286. PubMed ID: 35428777
[TBL] [Abstract][Full Text] [Related]
13. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
15. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
[TBL] [Abstract][Full Text] [Related]
16. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
17. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
